Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Eli Lilly and other ETFs, options, and stocks.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
43,000
Employees43,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
43,000
Employees43,000

LLY Key Statistics

Market cap
763.31B
Market cap763.31B
Price-Earnings ratio
88.06
Price-Earnings ratio88.06
Dividend yield
0.65%
Dividend yield0.65%
Average volume
3.91M
Average volume3.91M
High today
$809.12
High today$809.12
Low today
$799.00
Low today$799.00
Open price
$806.60
Open price$806.60
Volume
1.83M
Volume1.83M
52 Week high
$972.53
52 Week high$972.53
52 Week low
$637.00
52 Week low$637.00

LLY News

Seeking Alpha 1d
Eli Lilly trial update on kidney drug hurts Tectonic

Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a...

Eli Lilly trial update on kidney drug hurts Tectonic
TipRanks 1d
Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant concern about the...

TipRanks 2d
Eli Lilly price target lowered to $1,190 from $1,250 at Citi

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, th...

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More LLY News

The Motley Fool 5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's get...

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
The Motley Fool 5d
Why Eli Lilly Stock Topped the Market Today

Eli Lilly (LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks l...

Why Eli Lilly Stock Topped the Market Today
Investor's Business Daily 6d
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results

Novo Nordisk (NVO) on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly (L...

Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
Investor's Business Daily 7d
Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell?

Eli Lilly (LLY) stock continued its five-month downfall in late January after the company slashed its sales guidance for the fourth quarter. The company now ex...

Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell?
TipRanks 7d
Datadog, Booz Allen added to US 1 list at BofA, Lilly removed

BofA analysts added Datadog (DDOG) (DOOG) and Booz Allen (BAH) to the firm’s US 1 list while removing Eli Lilly (LLY) and renewing Apple (AAPL). The US 1 list i...

Zacks 7d
The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's - Zacks Investment Research

...

The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's - Zacks Investment Research
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.